Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
Natividad Pozo, … , Juan M. Sepúlveda, Pilar Sánchez-Gómez
Natividad Pozo, … , Juan M. Sepúlveda, Pilar Sánchez-Gómez
Published May 1, 2013
Citation Information: J Clin Invest. 2013;123(6):2475-2487. https://doi.org/10.1172/JCI63623.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 22

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth

  • Text
  • PDF
Abstract

Glioblastomas (GBMs) are very aggressive tumors that are resistant to conventional chemo- and radiotherapy. New molecular therapeutic strategies are required to effectively eliminate the subpopulation of GBM tumor–initiating cells that are responsible for relapse. Since EGFR is altered in 50% of GBMs, it represents one of the most promising targets; however, EGFR kinase inhibitors have produced poor results in clinical assays, with no clear explanation for the observed resistance. We uncovered a fundamental role for the dual-specificity tyrosine phosphorylation–regulated kinase, DYRK1A, in regulating EGFR in GBMs. We found that DYRK1A was highly expressed in these tumors and that its expression was correlated with that of EGFR. Moreover, DYRK1A inhibition promoted EGFR degradation in primary GBM cell lines and neural progenitor cells, sharply reducing the self-renewal capacity of normal and tumorigenic cells. Most importantly, our data suggest that a subset of GBMs depends on high surface EGFR levels, as DYRK1A inhibition compromised their survival and produced a profound decrease in tumor burden. We propose that the recovery of EGFR stability is a key oncogenic event in a large proportion of gliomas and that pharmacological inhibition of DYRK1A could represent a promising therapeutic intervention for EGFR-dependent GBMs.

Authors

Natividad Pozo, Cristina Zahonero, Paloma Fernández, Jose M. Liñares, Angel Ayuso, Masatoshi Hagiwara, Angel Pérez, Jose R. Ricoy, Aurelio Hernández-Laín, Juan M. Sepúlveda, Pilar Sánchez-Gómez

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Total
Citations: 1 8 4 10 12 7 7 6 1 4 6 4 70
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (70)

Title and authors Publication Year
Molecular roles in membrane receptor signaling pathways and cascade reactions in chondrocytes: a review.
Zhu Y, Zhu J, Wang X, Wang P, Liu R
Journal of molecular histology 2025
Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides
Bordeaux ZA, Reddy SV, Choi J, Braun G, McKeel J, Lu W, Yossef SM, Ma EZ, West CE, Kwatra SG, Kwatra MM
Scientific Reports 2024
Systems biology approach to identify biomarkers and therapeutic targets for colorectal cancer
Sadat Kalaki N, Ahmadzadeh M, Najafi M, Mobasheri M, Ajdarkosh H, Karbalaie Niya MH
Biochemistry and Biophysics Reports 2024
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs
Laham AJ, El-Awady R, Ayad MS, Wang N, Yan G, Boudreault J, Ali S, Lebrun JJ
npj Precision Oncology 2024
N-Benzylated 5-Hydroxybenzothiophene-2-carboxamides as Multi-Targeted Clk/Dyrk Inhibitors and Potential Anticancer Agents
Mostafa N, Chen PJ, Darwish SS, Su YC, Shiao MH, Piazza GA, Abadi AH, Engel M, Abdel-Halim M
Cancers 2024
Human Cytomegalovirus Dysregulates Cellular Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases and Sonic Hedgehog Pathway Proteins in Neural Astrocyte and Placental Models
Egilmezer E, Hamilton ST, Lauw G, Follett J, Sonntag E, Schütz M, Marschall M, Rawlinson WD
Viruses 2024
Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer
Carey-Smith SL, Kotecha RS, Cheung LC, Malinge S
International journal of molecular sciences 2024
DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity
Wang P, Sarkar S, Zhang M, Xiao T, Kong F, Zhang Z, Balasubramanian D, Jayaram N, Datta S, He R, Wu P, Chao P, Zhang Y, Washburn M, Florens LA, Nagarkar-Jaiswal S, Jaiswal M, Mohan M
eLife 2024
Design, synthesis, and structure–activity relationship studies of 6H-benzo[b]indeno[1,2-d]thiophen-6-one derivatives as DYRK1A/CLK1/CLK4/haspin inhibitors
Faouzi A, Arnaud A, Hallé F, Roussel J, Aymard M, Denavit V, Do CV, Mularoni A, Salah M, ElHady A, Pham TN, Bancet A, Le Borgne M, Terreux R, Barret R, Engel M, Lomberget T
RSC Medicinal Chemistry 2024
Topical GZ21T Inhibits the Growth of Actinic Keratoses in a UVB-Induced Model of Skin Carcinogenesis
Bordeaux ZA, Choi J, Braun G, Davis C, Marani M, Lee K, Samuel C, Adams J, Windom R, Pollizzi A, Kambala A, Cornman H, Reddy SV, Lu W, Oladipo OO, Alphonse MP, West CE, Kwatra SG, Kwatra MM
2023
DYRK1A-mediated PLK2 phosphorylation regulates the proliferation and invasion of glioblastoma cells
Tan S, Zhao J, Wang P
International journal of oncology 2023
Insights from the protein interaction Universe of the multifunctional “Goldilocks” kinase DYRK1A
Ananthapadmanabhan V, Shows KH, Dickinson AJ, Litovchick L
Frontiers in Cell and Developmental Biology 2023
Truncated Dyrk1A aggravates neuronal apoptosis by inhibiting ASF-mediated Bcl-x exon 2b inclusion.
Zhang S, Zhong J, Xu L, Wu Y, Xu J, Shi J, Gu Z, Li X, Jin N
CNS Neuroscience & Therapeutics 2023
Harmine reinforces the effects of regorafenib on suppressing cell proliferation and inducing apoptosis in liver cancer cells
Z Chen, J Li, S Zhu, Z Li, J Yu, J Wu, C Zhang, L Zeng
Experimental and therapeutic medicine 2022
IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas
R Gargini, B Segura-Collar, M Garranzo-Asensio, R Hortigüela, P Iglesias-Hernández, D Lobato-Alonso, M Moreno-Raja, S Esteban-Martin, J Sepúlveda-Sánchez, L Nevola, P Sánchez-Gómez
Neurotherapeutics 2022
The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target
M Rammohan, E Harris, R Bhansali, E Zhao, L Li, J Crispino
Oncogene 2022
Selective Macrocyclic Inhibitors of DYRK1A/B
C Powell, J Hatcher, J Jiang, P Vatsan, J Che, N Gray
ACS Medicinal Chemistry Letters 2022
GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
J Choi, Z Bordeaux, J McKeel, C Nanni, N Sutaria, G Braun, C Davis, M Miller, M Alphonse, S Kwatra, C West, M Kwatra
International journal of molecular sciences 2022
A Bioinformatics Evaluation of the Role of Dual-Specificity Tyrosine-Regulated Kinases in Colorectal Cancer
A Laham, R El-Awady, J Lebrun, M Ayad
Cancers 2022
Inhibition of DYRK1A, via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after myocardial infarction
Lan C, Chen C, Qu S, Cao N, Luo H, Yu C, Wang N, Xue Y, Xia X, Fan C, Ren H, Yang Y, Jose PA, Xu Z, Wu G, Zeng C
EBioMedicine 2022
A slow-cycling/quiescent cells subpopulation is involved in glioma invasiveness
Antonica F, Santomaso L, Pernici D, Petrucci L, Aiello G, Cutarelli A, Conti L, Romanel A, Miele E, Tebaldi T, Tiberi L
Nature Communications 2022
The Omnipresence of DYRK1A in Human Diseases
Deboever E, Fistrovich A, Hulme C, Dunckley T
International journal of molecular sciences 2022
Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System
Huizar FJ, Hill HM, Bacher EP, Eckert KE, Gulotty EM, Rodriguez KX, Tucker ZD, Banerjee M, Wiest O, Zartman J, Ashfeld BL
ChemMedChem 2022
DYRK1A regulates B-cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
Rahul S Bhansali, Malini Rammohan, Paul Lee, Anouchka P Laurent, Qiang Jeremy Wen, Praveen Suraneni, Yi-Chien Tsai, Silvia Jenni, Beat Bornhauser, Aurelie Siret, Corinne Fruit, Alexandra Pacheco-Benichou, Ethan Harris, Thierry Besson, Benjamin J Thompson, Young Ah Goo, Nobuko Hijiya, Maria Vilenchik, Shai Izraeli, Jean-Pierre Bourquin, Sebastien Malinge, John D Crispino
Journal of Clinical Investigation 2021
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells
A Recasens, SJ Humphrey, M Ellis, M Hoque, RH Abbassi, B Chen, M Longworth, EJ Needham, DE James, TG Johns, BW Day, M Kassiou, P Yang, L Munoz
Cell Death Discovery 2021
C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells
S Manzano, A Gutierrez-Uzquiza, P Bragado, C Sequera, Ó Herranz, M Rodrigo-Faus, P Jauregui, S Morgner, I Rubio, C Guerrero, A Porras
Cell Death and Disease 2021
DYRK1A phosphorylates MEF2D and decreases its transcriptional activity
P Wang, J Zhao, X Sun
Journal of Cellular and Molecular Medicine 2021
Diabetic Kinome Inhibitors—A New Opportunity for β-Cells Restoration
B Pucelik, A Barzowska, JM Dąbrowski, A Czarna
International journal of molecular sciences 2021
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
MF Lindberg, L Meijer
International journal of molecular sciences 2021
K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR
P Zhang, Z Zhang, Y Fu, Y Zhang, MP Washburn, L Florens, M Wu, C Huang, Z Hou, M Mohan
Cell Death and Disease 2021
Phosphorylation regulates cullin-based ubiquitination in tumorigenesis
Y Chen, X Shao, J Cao, H Zhu, B Yang, Q He, M Ying
Acta pharmaceutica Sinica. B 2021
Targeting DYRK1A/B kinases to modulate p21‐cyclin D1‐p27 signalling and induce anti‐tumour activity in a model of human glioblastoma
AJ Massey, K Benwell, M Burbridge, A Kotschy, DL Walmsley
Journal of Cellular and Molecular Medicine 2021
Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies
M Tarpley, HO Oladapo, D Strepay, TB Caligan, L Chdid, H Shehata, JR Roques, R Thomas, CP Laudeman, RU Onyenwoke, DB Darr, KP Williams
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2021
TROAP switches DYRK1 activity to drive hepatocellular carcinoma progression
L Li, JR Wei, Y Song, S Fang, Y Du, Z Li, TT Zeng, YH Zhu, Y Li, XY Guan
Cell Death and Disease 2021
Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome
W Stensen, U Rothweiler, RA Engh, MR Stasko, I Bederman, AC Costa, A Fugelli, JS Svendsen
Pharmaceuticals (Basel, Switzerland) 2021
The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities
J Boni, C Rubio-Perez, N López-Bigas, C Fillat, S de la Luna
Cancers 2020
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis
AJ Laham, M Saber-Ayad, R El-Awady
Cellular and Molecular Life Sciences 2020
A novel de novo heterozygous DYRK1A mutation causes complete loss of DYRK1A function and developmental delay
KS Lee, M Choi, DW Kwon, D Kim, JM Choi, AK Kim, Y Ham, SB Han, S Cho, CK Cheon
Scientific Reports 2020
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas
R Gargini, B Segura-Collar, B Herránz, V García-Escudero, A Romero-Bravo, FJ Núñez, D García-Pérez, J Gutiérrez-Guamán, A Ayuso-Sacido, J Seoane, A Pérez-Núñez, JM Sepúlveda-Sánchez, A Hernández-Laín, MG Castro, R García-Escudero, J Ávila, P Sánchez-Gómez
Science Translational Medicine 2020
Minibrain-related kinase/dual-specificity tyrosine-regulated kinase 1B implication in stem/cancer stem cells biology
N Kokkorakis, M Gaitanou
World journal of stem cells 2020
The EGFR-TMEM167A-p53 Axis Defines the Aggressiveness of Gliomas
B Segura-Collar, R Gargini, E Tovar-Ambel, E Hernández-SanMiguel, C Epifano, IP de Castro, A Hernández-Laín, S Casas-Tintó, P Sánchez-Gómez
Cancers 2020
Midkine signaling maintains the self-renewal and tumorigenic capacity of glioma initiating cells
I López-Valero, D Dávila, J González-Martínez, N Salvador-Tormo, M Lorente, C Saiz-Ladera, S Torres, E Gabicagogeascoa, S Hernández-Tiedra, E García-Taboada, M Mendiburu-Eliçabe, F Rodríguez-Fornés, R Sánchez-Domínguez, JC Segovia, P Sánchez-Gómez, A Matheu, JM Sepúlveda, G Velasco
Theranostics 2020
Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence
X Xu, Q Liu, C Zhang, S Ren, L Xu, Z Zhao, H Dou, P Li, X Zhang, Y Gong, C Shao
Cell Death and Disease 2019
A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response
J Roewenstrunk, CD Vona, J Chen, E Borras, C Dong, K Arató, E Sabidó, MS Huen, S de la Luna
Scientific Reports 2019
Chimeric NANOG repressors inhibit glioblastoma growth in vivo in a context-dependent manner
M Kuciak, C Mas, I Borges, P Sánchez-Gómez, AR i Altaba
Scientific Reports 2019
Precision Revisited: Targeting Microcephaly Kinases in Brain Tumors
G Pallavicini, GE Berto, FD Cunto
International journal of molecular sciences 2019
Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma
E Hernández-SanMiguel, R Gargini, T Cejalvo, B Segura-Collar, P Núñez-Hervada, R Hortigüela, JM Sepúlveda-Sánchez, A Hernández-Laín, A Pérez-Núñez, E Sanz, P Sánchez-Gómez
Oxidative medicine and cellular longevity 2019
DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
Y Li, K Ding, X Hu, L Wu, D Zhou, M Rao, N Lin, C Zhang
Journal of Cellular and Molecular Medicine 2019
[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors
C Lechner, M Flaßhoff, H Falke, L Preu, N Loaëc, L Meijer, S Knapp, A Chaikuad, C Kunick
Molecules (Basel, Switzerland) 2019
NFκB activation in differentiating glioblastoma stem-like cells is promoted by hyaluronic acid signaling through TLR4
E Ferrandez, O Gutierrez, DS Segundo, JL Fernandez-Luna
Scientific Reports 2018
DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers
S Li, C Xu, Y Fu, PJ Lei, Y Yao, W Yang, Y Zhang, MP Washburn, L Florens, M Jaiswal, M Wu, M Mohan
Nucleic Acids Research 2018
Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity
K Kumar, PM Ung, P Wang, H Wang, H Li, MK Andrews, AF Stewart, A Schlessinger, RJ DeVita
European Journal of Medicinal Chemistry 2018
Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma
KL Uhl, CR Schultz, D Geerts, AS Bachmann
Cancer Cell International 2018
A facile consensus ranking approach enhances virtual screening robustness and identifies a cell-active DYRK1α inhibitor
ME Mavrogeni, F Pronios, D Zareifi, S Vasilakaki, O Lozach, L Alexopoulos, L Meijer, V Myrianthopoulos, E Mikros
Future Medicinal Chemistry 2018
ANGUSTIFOLIA Regulates Actin Filament Alignment for Nuclear Positioning in Leaves
K Iwabuchi, H Ohnishi, K Tamura, Y Fukao, T Furuya, K Hattori, H Tsukaya, I Hara-Nishimura
Plant physiology 2018
A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis
A Carvalho, J Chu, C Meinguet, R Kiss, G Vandenbussche, B Masereel, J Wouters, A Kornienko, J Pelletier, V Mathieu
European Journal of Pharmacology 2017
ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA
A Talamillo, L Grande, P Ruiz-Ontañon, C Velasquez, P Mollinedo, S Torices, P Sanchez-Gomez, A Aznar, A Esparis-Ogando, C Lopez-Lopez, C Lafita, MT Berciano, JA Montero, A Vazquez-Barquero, V Segura, NT Villagra, A Pandiella, M Lafarga, J Leon, JA Martinez-Climent, V Sanz-Moreno, JL Fernandez-Luna
Oncogene 2016
An ID2-dependent mechanism for VHL inactivation in cancer
SB Lee, V Frattini, M Bansal, AM Castano, D Sherman, K Hutchinson, JN Bruce, A Califano, G Liu, T Cardozo, A Iavarone, A Lasorella
Nature 2016
Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of Capicua
L Yang, S Paul, KG Trieu, LG Dent, F Froldi, M Forés, K Webster, KR Siegfried, S Kondo, K Harvey, L Cheng, G Jiménez, SY Shvartsman, A Veraksa
Proceedings of the National Academy of Sciences 2016
A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma
A Radhakrishnan, V Nanjappa, R Raja, G Sathe, VN Puttamallesh, AP Jain, SM Pinto, SA Balaji, S Chavan, NA Sahasrabuddhe, PP Mathur, MM Kumar, TS Prasad, V Santosh, G Sukumar, JA Califano, A Rangarajan, D Sidransky, A Pandey, H Gowda, A Chatterjee
Scientific Reports 2016
DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3
BJ Thompson, R Bhansali, L Diebold, DE Cook, L Stolzenburg, AS Casagrande, T Besson, B Leblond, L Desire, S Malinge, JD Crispino
Journal of Experimental Medicine 2015
A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastoma
KC Kondapalli, JP Llongueras, V Capilla-González, H Prasad, A Hack, C Smith, H Guerrero-Cázares, A Quiñones-Hinojosa, R Rao
Nature Communications 2015
Identification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library
B Guerra, J Hochscherf, NB Jensen, OG Issinger
Molecular and Cellular Biochemistry 2015
A Survey of Marine Natural Compounds and Their Derivatives with Anti-Cancer Activity Reported in 2012
W Sawadogo, R Boly, C Cerella, M Teiten, M Dicato, M Diederich
Molecules (Basel, Switzerland) 2015
DYRK1A Controls HIV-1 Replication at a Transcriptional Level in an NFAT Dependent Manner
T Booiman, VV Loukachov, KA van Dort, AB van Wout, NA Kootstra, A Marcello
PloS one 2015
Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma
González-Gómez P, Crecente-Campo J, Zahonero C, de la Fuente M, Hernández-Laín A, Mira H, Sánchez-Gómez P, Garcia-Fuentes M
Oncotarget 2015
DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis
P Fernández-Martínez, C Zahonero, P Sánchez-Gómez
Molecular & Cellular Oncology 2014
Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors
C Schmitt, D Kail, M Mariano, M Empting, N Weber, T Paul, RW Hartmann, M Engel
PloS one 2014
EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy
C Zahonero, P Sánchez-Gómez
Cellular and Molecular Life Sciences 2014
Sleeping Beauty Mouse Models Identify Candidate Genes Involved in Gliomagenesis
I Vyazunova, VI Maklakova, S Berman, I De, MD Steffen, W Hong, H Lincoln, AS Morrissy, MD Taylor, K Akagi, CW Brennan, FJ Rodriguez, LS Collier, AC Wilber
PloS one 2014

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Posted by 4 X users
Referenced in 8 patents
Reddited by 1
146 readers on Mendeley
See more details